[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-operative-hematoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-operative-hematoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100560277","seroma-and-hematoma-rates-maxigesic-iv-vs-ketorolac-in-breast-cancer-surgery-100560277",false,"NCT06575049","Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery","Comparative Analysis of Seroma and Hematoma Rates: MAXIGESIC vs. Ketorolac in Breast Cancer Surgery Patients","Inclusion Criteria:\n\n* Systemic performance status 0-2 according to ECOG criteria\n* Patients with adequate renal function: serum Cr 1.4 mg\u002FdL or less\n* Patients with adequate liver function Bilirubin, AST\u002FALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal\n* Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection)\n* Patients undergoing breast-conserving surgery with ALND (mastectomy and axillary dissection)\n* Patients who voluntarily decided to participate in this study and signed a written informed consent form\n\nExclusion Criteria:\n\n* Patients undergoing immediate reconstruction operation\n* Patients with drug allergies to painkillers and anti-inflammatory drugs\n* Patients with a physical condition that would interfere with understanding and submitting the consent form","FEMALE","20 Years","70 Years",{"count":20,"type":21},60,"ESTIMATED","3 Months","OBSERVATIONAL","The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.",[26,27,28,29],"Breast Cancer","Post-Operative Hematoma","Seroma as Procedural Complication","Post-Op Complication","NOT_YET_RECRUITING","2024-09-02",{"date":33,"type":34},"2024-09-19","ACTUAL",{"date":36,"type":21},"2025-05-01",{"date":38,"type":21},"2026-02-20",{"name":40,"class":41},"Seoul National University Hospital","OTHER"]